Following countries such as the United States and Japan, the EU may also approve Rhettsivir for the treatment of newly-crowned pneumonia. The head of the European Drug Administration (EMA), Guido Lasi (Guido Rasi), told a parliamentary hearing on the same day,Novel coronavirus pneumonia (Remdesivir), a new antiviral drug developed by Gilead, will be approved by the company in recent days to treat the new crown pneumonia. Reed "Radcivir is likely to get a conditional listing permit in the near future," rassie said
The novel coronavirus pneumonia has been recommended by the European Medicines Agency for the Reed crown to be treated with "no more than" drugs.
In addition to radcivir, monoclonal antibody based therapies may also be used in the near future, RASI said. It is reported that the treatment can "neutralize" the new coronavirus.
Gilead R & D ridcivir was originally planned to be used for diseases such as Ebola haemorrhagic fever and Middle East respiratory syndrome. Novel coronavirus pneumonia was approved by the US Food and Drug Administration (FDA) in March 23rd. Reed approved the orphan drug certification in March 23rd. In May 1st, the emergency use authorization was granted to allow the emergency use of "new" acute pneumonia. Novel coronavirus pneumonia was also approved by Reed in May 7th. Many countries also conducted novel coronavirus pneumonia trials with Reed's way.